Sandoz announces exclusive global collaboration with Biocon on next-generation biosimilars

Sandoz, a Novartis division and the global leader in biosimilars, announced a global partnership with Asia’s premier biopharmaceuticals company, Biocon, to develop, manufacture and commercialize multiple biosimilars in immunology and oncology for patients worldwide.

• Source: Sandoz
• 602
• January 23, 2018